Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Mediterranean Diet for Psoriasis

In this study, participants will have 3 or 4 total study visits over approximately 10 total weeks. There is a two week medication washout period in between the 1st and 2nd visits.

Official registry: https://clinicaltrials.gov/study/NCT06399432 · University Hospitals Cleveland Medical Center · enrollment listed as 36

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Mediterranean Diet. The registry lists allocation as randomized. In this study, participants will have 3 or 4 total study visits over approximately 10 total weeks.

They plan to enroll about 36 people at Cleveland. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors

Interventions: Mediterranean Diet

Primary outcome (registry wording): Percentage of participants who had a change in blood monocytes profiles.

Who it is for (from inclusion criteria)

  • Ages 18 Years to 94 Years
  • Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening
  • Have moderate to severe plaque psoriasis at Baseline as defined by
  • sPGA ≥3 (moderate to severe) OR
  • Must have been prescribed, per standard-of-care, an Anti-IL-17 or Anti-IL-23 therapy for psoriasis, which the patient has not yet started, but is willing to start during the study
  • Eligible therapies are Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab, and Tildrakizumab
  • Must be in good health (except for psoriasis) as judged by the Investigator, based on medical history and physical examination
  • Must be eligible for a weight loss program, defined as being in good general health and having a body-mass index (BMI) between 25 to 40

Public study contact (from the registry)

Kym Warner

216-844-7546

Kymberlyn.Warner@UHhospitals.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBerlin, State of Berlin
Not a traditional drug phase: testing Glucocorticoid treatment for Osteoporosis

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.

NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit

RecruitingPhase 3Ciudad Autonoma de Buenos Aires, Buenos Aires
Phase 3: testing Deucravacitinib for Plaque Psoriasis

The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.

NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

FAQ about this NCT record

Is NCT06399432 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06399432?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06399432?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary